Cargando…

The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer

PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivekanandan, S., Landau, D.B., Counsell, N., Warren, D.R., Khwanda, A., Rosen, S.D., Parsons, E., Ngai, Y., Farrelly, L., Hughes, L., Hawkins, M.A., Fenwick, J.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554783/
https://www.ncbi.nlm.nih.gov/pubmed/28816160
http://dx.doi.org/10.1016/j.ijrobp.2017.04.026
_version_ 1783256844610830336
author Vivekanandan, S.
Landau, D.B.
Counsell, N.
Warren, D.R.
Khwanda, A.
Rosen, S.D.
Parsons, E.
Ngai, Y.
Farrelly, L.
Hughes, L.
Hawkins, M.A.
Fenwick, J.D.
author_facet Vivekanandan, S.
Landau, D.B.
Counsell, N.
Warren, D.R.
Khwanda, A.
Rosen, S.D.
Parsons, E.
Ngai, Y.
Farrelly, L.
Hughes, L.
Hawkins, M.A.
Fenwick, J.D.
author_sort Vivekanandan, S.
collection PubMed
description PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy. METHODS AND MATERIALS: Dosimetric and survival data were analyzed for 78 patients. The whole heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles (LV/RV-Wall) were outlined on radiation therapy planning scans, and differential dose-volume histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the average dDVH and the 10 highest-ranked structure-specific principal components (PCs). ECGs at baseline and 6 months after radiation therapy were analyzed for 53 patients, dichotomizing patients according to presence or absence of “any ECG change” (conduction or ischemic/pericarditis-like change). All-cause death rate (DR) was analyzed from the start of treatment using Cox regression. RESULTS: 38% of patients had ECG changes at 6 months. On univariable analysis, higher scores for LA-Wall-PC6, Heart-PC6, “any ECG change,” and larger planning target volume (PTV) were significantly associated with higher DR (P=.003, .009, .029, and .037, respectively). Heart-PC6 and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63 to 69 Gy. Cardiac doses ≥63 Gy were concentrated in the LA-Wall, and consequently Heart-PC6 was highly correlated with LA-Wall-PC6. “Any ECG change,” LA-Wall-PC6 scores, and PTV size were retained in the multivariable model. CONCLUSIONS: We found associations between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63 to 69 Gy in this small cohort of patients.
format Online
Article
Text
id pubmed-5554783
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier Science Inc
record_format MEDLINE/PubMed
spelling pubmed-55547832017-09-01 The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer Vivekanandan, S. Landau, D.B. Counsell, N. Warren, D.R. Khwanda, A. Rosen, S.D. Parsons, E. Ngai, Y. Farrelly, L. Hughes, L. Hawkins, M.A. Fenwick, J.D. Int J Radiat Oncol Biol Phys Clinical Investigation PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy. METHODS AND MATERIALS: Dosimetric and survival data were analyzed for 78 patients. The whole heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles (LV/RV-Wall) were outlined on radiation therapy planning scans, and differential dose-volume histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the average dDVH and the 10 highest-ranked structure-specific principal components (PCs). ECGs at baseline and 6 months after radiation therapy were analyzed for 53 patients, dichotomizing patients according to presence or absence of “any ECG change” (conduction or ischemic/pericarditis-like change). All-cause death rate (DR) was analyzed from the start of treatment using Cox regression. RESULTS: 38% of patients had ECG changes at 6 months. On univariable analysis, higher scores for LA-Wall-PC6, Heart-PC6, “any ECG change,” and larger planning target volume (PTV) were significantly associated with higher DR (P=.003, .009, .029, and .037, respectively). Heart-PC6 and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63 to 69 Gy. Cardiac doses ≥63 Gy were concentrated in the LA-Wall, and consequently Heart-PC6 was highly correlated with LA-Wall-PC6. “Any ECG change,” LA-Wall-PC6 scores, and PTV size were retained in the multivariable model. CONCLUSIONS: We found associations between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63 to 69 Gy in this small cohort of patients. Elsevier Science Inc 2017-09-01 /pmc/articles/PMC5554783/ /pubmed/28816160 http://dx.doi.org/10.1016/j.ijrobp.2017.04.026 Text en Crown Copyright © Published by Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Clinical Investigation
Vivekanandan, S.
Landau, D.B.
Counsell, N.
Warren, D.R.
Khwanda, A.
Rosen, S.D.
Parsons, E.
Ngai, Y.
Farrelly, L.
Hughes, L.
Hawkins, M.A.
Fenwick, J.D.
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title_full The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title_fullStr The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title_full_unstemmed The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title_short The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
title_sort impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554783/
https://www.ncbi.nlm.nih.gov/pubmed/28816160
http://dx.doi.org/10.1016/j.ijrobp.2017.04.026
work_keys_str_mv AT vivekanandans theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT landaudb theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT counselln theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT warrendr theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT khwandaa theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT rosensd theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT parsonse theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT ngaiy theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT farrellyl theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT hughesl theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT hawkinsma theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT fenwickjd theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT vivekanandans impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT landaudb impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT counselln impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT warrendr impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT khwandaa impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT rosensd impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT parsonse impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT ngaiy impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT farrellyl impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT hughesl impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT hawkinsma impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer
AT fenwickjd impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer